You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company said testing revenues rose 54 percent during the quarter, and that it provided 63 percent more patient results year over year.
The increase in total revenues was driven primarily by sales of Natera's Panorama and Horizon reproductive health tests.
CareDx first sued Natera in April 2019, accusing the company of trying to mislead patients and clinicians about the superiority of its Prospera transplant test.
The Milwaukee, Wisconsin-based firm is part of a growing biotech ecosystem in the region, which has particular expertise in transplant medicine.
The patent, which was awarded Jan. 7, covers cell-free DNA-based diagnostic methods, including those used in transplant medicine.
The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.
Effective Feb. 3, 2020, the donor-derived cell-free DNA test will be covered for all kidney transplant recipients, including those with multiple kidney transplants.
The firm said that in its product pipeline in 2019 it focused on organ transplant and lung health, involving use of its multiplexed research-use TORdx Lung tests.
A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.